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Introduction
Chronic obstructive pulmonary disease (COPD) is a major 
contributor to global morbidity and mortality; it aﬀ ects an 
estimated 210 million people worldwide,1 places ﬁ nancial 
burden on health-care systems,2 and is projected to be the 
third most frequent cause of death by 2020.3 COPD has 
systemic impact and skeletal muscle dysfunction is a well 
recognised extrapulmonary manifestation, with 
preferential weakness and atrophy noted in the lower 
limbs—mainly as a consequence of physical inactivity.4 
Quadriceps dysfunction and the subsequent exercise 
intolerance are associated with increased service use and 
poor prognosis, independent of lung function.5–7 These 
and other COPD-related symptoms, such as breathlessness, 
can be eﬀ ectively managed with exercise training as part of 
pulmonary rehabilitation,8 which is internationally 
accepted as a ﬁ rst-line disease management strategy.9 
Nonetheless, issues with service provision, uptake, and 
adherence—eg, lack of transport, restricting symptoms, or 
social isolation—restrict its reach for patient beneﬁ t, 
particularly for those most impaired by their disease.10,11
A proposed alternative treatment is neuromuscular 
electrical stimulation (NMES). This uses a portable 
stimulator and skin electrodes to produce a controlled 
contraction of the muscle.12 NMES can be self-
administered at home, unsupervised, and carries a low 
metabolic load, providing an acceptable therapy for 
patients living with a high-symptom burden who ﬁ nd 
travel to clinics and classes diﬃ  cult.13 The strengthening 
eﬀ ect of NMES is well established among patients with 
severe disease compared with no exercise 12 and with 
lower limb resistance training.14 The eﬀ ect of NMES on 
functional exercise performance is not yet clear but is 
important to understand because this is a key 
determinant of health status, and relates to overall 
survival in this group.6,12 Moreover, data to help to embed 
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Summary
Background Skeletal muscle dysfunction and exercise intolerance are common in severe chronic obstructive 
pulmonary disease (COPD). We assessed the eﬀ ectiveness of neuromuscular electrical stimulation (NMES) as a 
home-based exercise therapy.
Methods In this double-blind, placebo-controlled trial, undertaken across three UK National Health Service sites, we 
randomly assigned (1:1) adults with COPD, a forced expiratory volume in 1 s (FEV1) less than 50% predicted, and 
incapacitating breathlessness (Medical Research Council dyspnoea scale ≥4) to receive active or placebo NMES, daily 
over a 6-week period. Randomisation was by an independent system using minimisation to balance age, GOLD stage, 
and quadriceps strength. Participants and outcome assessors were masked to group allocation. The primary endpoint 
was change in 6-min walk test (6MWT) distance at 6 weeks. Analysis was by intention to treat. The trial was registered 
as ISRCTN15985261 and is now closed.
Findings Between June 29, 2012, and July 4, 2014, we enrolled 73 participants, of whom 52 participants were randomly 
assigned; 25 to receive active NMES and 27 to placebo NMES. Change in 6MWT distance was greater in the active 
NMES group (mean 29·9 [95% CI 8·9 to 51·0]) compared with in the placebo group (–5·7 [–19·9 to 8·4]; mean 
diﬀ erence at 6 weeks 35·7 m [95% CI 10·5 to 60·9]; p=0·005). Sensitivity analyses for complete-cases and adjustment 
for baseline values showed similar results. 6 weeks after stopping the intervention the eﬀ ect waned (7·3 m [95% CI 
–32·5 to 47·0]; p=0·50). The proportion of participants who had adverse events was similar between groups (ﬁ ve 
[20%] in the active NMES group and nine [33%] in the placebo group). Two participants, one from each group, 
reported persistent erythema, which was considered to be possibly related to NMES and the use of adhesive electrodes.
Interpretation NMES improves functional exercise capacity in patients with severe COPD by enhancing quadriceps 
muscle mass and function. These data support the use of NMES in the management of patients unable to engage 
with conventional pulmonary rehabilitation. More work is needed to study how to maintain the eﬀ ect.
Funding National Institute for Health Research.
Copyright © Maddocks et al. Open Access article distributed under the terms of CC BY.
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NMES within routine clinical practice are lacking—for 
example, it is unclear if training eﬀ ects can be maintained 
and how they translate into everyday beneﬁ t to patients.
Therefore, this trial aimed to determine the eﬀ ectiveness 
of NMES on functional exercise capacity in breathless 
patients with severe COPD. Our null hypothesis was that 
patients receiving NMES to both quadriceps over 6 weeks 
would have no diﬀ erence in change in exercise 
performance, compared with patients receiving a placebo 
intervention.
Methods
Study design and participants
In this parallel, two-group, double-blind, placebo-
controlled trial with nested qualitative interviews, which 
was conducted and reported according to CONSORT 
guidelines, recruitment took place across three National 
Health Service trusts in London, UK. Patients were 
screened at multidisciplinary respiratory and palliative 
care meetings and across pulmonary rehabilitation 
services. Patients were eligible if they were aged 18 years 
or older, with a spirometrically deﬁ ned diagnosis of 
COPD consistent with GOLD criteria (forced expiratory 
volume in 1 s:forced vital capacity [FEV1:FVC] <70%), 
severe respiratory impairment (FEV1 % predicted ≤50), 
and incapacitating breathlessness (Medical Research 
Council dyspnoea scale 4 or 5).15 Patients were excluded if 
they had an implanted cardiac pacemaker, a coexisting 
neurological condition, had changed their medication, or 
had experienced an acute exacerbation requiring a 
hospital admission or systemic corticosteroids in the 
preceding 4 weeks. This time period was chosen to allow 
patients to regain a degree of function that would allow 
engagement with the treatment programme, and so not 
to impede eﬀ orts to implement policy for patients to 
commence pulmonary rehabilitation within 4 weeks of 
hospital discharge.9 We also excluded current regular 
exercisers, deﬁ ned as those enrolled in pulmonary 
rehabilitation or undertaking structured exercise training 
(≥3 times per week) within the past month. All 
participants gave written informed consent before trial 
entry in accordance with the principles of Good Clinical 
Practice and the Declaration of Helsinki. The trial 
protocol was pre-registered with ISRCTN (Ref 15985261) 
and approved by the London Camberwell St Giles 
Research Ethics Committee (Ref 12/LO/0263).
Randomisation and masking
After baseline assessment, participants were randomly 
assigned (1:1) at the individual level, using an independent 
web-based randomisation system within the independent 
UK Clinical Research Collaboration-registered King’s 
Clinical Trials Unit (London, UK). Using a hybrid 
minimisation method, 20% of participants were entered 
using simple randomisation and 80% entered using 
computer-generated probabilistic minimisation to balance 
three potential confounders; age (<65 years or ≥65 years), 
GOLD stage (III or IV), and quadriceps strength (<20 kg 
Research in context
Evidence before this study
Pulmonary rehabilitation has known eﬀ ectiveness on physical 
function and health status in chronic obstructive pulmonary 
disease (COPD), but uptake and adherence are restricted when 
patients have more severe disease. As a result, alternative, more 
accessible exercise therapies are sought. Home-based 
neuromuscular electrical stimulation (NMES) is one such 
approach, which is gaining interest. We extended our previous 
Cochrane systematic review by searching MEDLINE, Embase, and 
CINAHL databases with the terms “exp Electric Stimulation 
Therapy”, “muscle* or muscular or neuromuscular or neuro-
muscular and electric* and stimulant*” and “NMES”, without 
language restrictions for randomised trials published up to Nov 1, 
2015. We identiﬁ ed 15 trials across patients with COPD, chronic 
heart failure, and cancer, randomising a total of 445 patients to 
NMES oﬀ ered alone or as an adjunct to another exercise 
programme. Common weaknesses with the methods included 
limited placebo models and no outcome assessor masking. A 
pooled estimate of eﬀ ect indicated that NMES improved 
quadriceps strength by a standardised mean diﬀ erence of 0·9 
(95% CI 0·33–1·46). There was inconclusive evidence regarding an 
eﬀ ect on functional exercise capacity, and no data for the 
duration of any eﬀ ect following withdrawal of NMES, which is 
important to understand before uptake into clinical practice.
Added value of this study
This trial provides high-quality evidence supporting the use of 
NMES to manage exercise intolerance among patients with 
severe COPD experiencing disability due to breathlessness. To 
our knowledge, our study is the ﬁ rst powered with exercise 
capacity as a primary endpoint, and to include follow-up data. 
NMES led to a clinically meaningful improvement in 6-min walk 
test distance at 6 weeks in this patient group compared with the 
placebo group. During interviews, participants also reported 
greater ease in undertaking activities of daily living following 
NMES. However, the eﬀ ect waned after withdrawal of NMES 
(a further 6 weeks). This short duration of eﬀ ect underscores the 
need to carefully time use within clinical practice, and to explore 
longer programmes, which are supported by the low risk proﬁ le 
observed here.
Implications of all the available evidence
Current evidence supports the use of NMES in the management 
of patients who are unable to engage with pulmonary 
rehabilitation programmes. Staﬀ  within these services could oﬀ er 
NMES as an extension of their current scope of practice. Future 
research should consider trialling longer or more comprehensive 
NMES based programmes, which include education and 
behaviour change components. 
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or ≥20 kg). Following randomisation to active or placebo 
NMES, the Clinical Trials Unit informed trial staﬀ  via 
secure email. The trial coordinator, who arranged 
subsequent masked assessment visits, was informed of 
trial entry but not group allocation. Participants were not 
informed of group allocation. Trial physiotherapists and 
nurses were informed of group allocation and selected an 
active or placebo NMES device accordingly. Two linked 
Good Clinical Practice compliant online data entry 
systems (InferMed, London, UK; MACRO version 4) were 
created to maintain blinding; the ﬁ rst was used by 
physiotherapists and nurses for data regarding compliance 
and safety, and the second was used by trial assessors for 
outcome data. The statistician undertaking the primary 
analysis (WG) was masked to group allocation.
Procedures
Treating clinicians identiﬁ ed potentially eligible patients 
and oﬀ ered them a written information sheet. Interested 
patients attended a face-to-face appointment to conﬁ rm 
their eligibility, provide consent, and complete baseline 
assessments.
The therapy was a self-administered, 6-week programme 
consisting of 30 min of daily bilateral NMES to the 
quadriceps. NMES uses a battery powered unit to produce 
a controlled muscular contraction, via self-adhesive 
electrodes, equivalent to 15–25% of a maximum voluntary 
contraction (MVC). NMES was delivered with a two-
channel MicroStim Exercise Stimulator MS2v2 (Odstock 
Medical Ltd, Wiltshire, UK) and self-adhesive PALS 
platinum electrodes (10 cm × 13 cm) placed over the distal 
and proximal body of each quadriceps. Devices delivered 
current ﬁ xed at 50 Hz frequency in 350 μs pulses over an 
on:oﬀ  duty cycle, which increased on a weekly basis from 
2:15 s to 5:20 s to 10:15 s, remaining constant thereafter. 
These parameters were selected to minimise skin 
irritation and muscular fatigue.
Active devices had an amplitude range of 0−120 mA, 
whereas placebo devices had a range of 0−20 mA (both 
over 1 KΩ). The placebo amplitude range was selected 
following piloting of four diﬀ erent maximum outputs 
(12–30 mA) to provide a sensory stimulus that was 
detectable by the participant, but insuﬃ  cient to elicit a 
tetanic muscular contraction. Devices were outwardly 
identical apart from a concealed “A” or “B” label, and were 
controlled by a physiotherapist or nurse who was aware of 
the participant’s group allocation. The same 
physiotherapist or nurse instructed every participant on 
how to use the device during a standardised 30 min 
face-to-face training protocol, which included supervising 
the ﬁ rst self-administered set-up in hospital or home 
depending on participant preference. Participants were 
asked to increase the amplitude until the stimulation 
intensity was comfortable and not painful. To maximise 
compliance to the intervention, training was 
supplemented by standardised written instructions and a 
self-report diary, weekly telephone calls to troubleshoot 
any practical problems and to prompt participants to 
increase the stimulation amplitude as tolerated, and 
home visits to reinstruct patients as required. All were 
completed by the physiotherapist or nurse, and 
communication was standardised to maintain participant 
masking. Both active and control groups used their 
devices for 6 weeks, after which they were collected by the 
physiotherapist or nurse.
Follow-up assessments were completed 6 weeks and 
12 weeks after randomisation by face-to-face visits. The 
trial coordinator (masked to group allocation) 
undertook physical assessments; questionnaires were 
self-completed independently by participants. Treatment 
compliance was assessed with a concealed in-built logger, 
which recorded the number of times the NMES device 
had been switched on and total duration of use. All other 
indicated rehabilitation treatments were permitted 
during the trial.
Outcomes
The primary outcome was change in distance covered in 
the 6-min walk test (6MWT) from baseline to 6 weeks. 
The 6MWT is a self-paced test of functional exercise 
Figure 1: Trial proﬁ le
NMES=neuromuscular electrical stimulation. MRC=Medical Research Council.
73 patients assessed for eligibility  11 did not meet inclusion criteria
 3 implanted metal prostheses
 3 on MRC score
 2 on GOLD stage
 2 unable to give informed consent
 1 current regular exerciser
10 declined to participate
 6 were uninterested
 2 felt too unwell
 2 scheduling diﬃculties52 patients randomly assigned
25 were allocated to active NMES 27 were allocated to placebo NMES
2 lost to follow-up 
 (refused hospital visit)
1 withdrew (became 
 housebound)
1 withdrew (bereavement)
25 analysed at 6 weeks
 22 baseline and follow-up data
 3 missing data imputed
27 analysed at 6 weeks
 26 baseline and follow-up data
 1 missing data imputed
2 withdrew (admitted to 
 hospital, acutely unwell)
1 withdrew (family 
 encouraged to withdraw)
2 lost to follow-up
3 withdrew (too unwell to 
 participate)
1 withdrew (new diagnosis 
 of cancer)
3 lost to follow-up
25 analysed at 12 weeks
 17 baseline and follow-up data
 8 missing data imputed
27 analysed at 12 weeks
 19 baseline and follow-up data
 8 missing data imputed
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capacity in which patients are asked to walk as far as 
possible in 6 min along a ﬂ at corridor.16 Tests were 
conducted according to European Respiratory Society/
American Thoracic Society Technical Standard.17
Secondary outcomes related to skeletal muscle were 
quadriceps twitch tension (TwQ) elicited in an 
unpotentiated state by supramaximal femoral nerve 
stimulation,18 isometric quadriceps maximum voluntary 
contraction (QMVC) assessed using a chair-mounted 
strain gauge,19 with percent predicted QMVC calculated 
using a disease-speciﬁ c and sex-speciﬁ c regression 
equation,20 rectus femoris cross-sectional area (RFCSA) 
assessed by ultrasonography,21 and whole-body fat-free 
mass assessed by bioelectrical impedance analysis and 
disease-speciﬁ c regression equations.22 Physical activity 
level was assessed as mean daily step count, time spent 
upright, and number of sit-to-stand transitions using a 
multiaxial accelerometer (activPAL; PAL Technologies, 
Glasgow, UK) worn for 21 h or more per day over 6 days.23
We assessed health-related quality of life using the 
EuroQol 5-dimension (EQ-5D; visual analogue scale 
0–100; lower score indicates poorer quality of life),24 and 
health status using the St George’s Respiratory 






Men 11 (44%) 10 (37%)
Women 14 (56%) 17 (63%)
Age (years) 70 (11) 69 (9)
Weight (kg) 74·1 (20·1) 75·7 (20·1)
BMI (kg/m2) 25·7 (5·9) 27·8 (8·2)
Smoking status
Current 5 (20%) 3 (11%)
Previous 19 (76%) 23 (85%)
Never 1 (4%) 1 (4%)
Pack-year history 49 (18) 49 (20)
Spirometry
FEV1 (L) 0·82 (0·29) 0·80 (0·49)
FEV1 % predicted 30·8 (11·1) 30·7 (12·7)
FVC (L) 2·31 (0·79) 2·02 (0·90)
FVC % predicted 70·0 (19·0) 58·3 (21·0)
GOLD stage
III 12 (48%) 11 (41%) 
IV 13 (52%) 16 (59%)
SpO2 on air 93 (3) 92 (8)
MRC score
4 18 (72%) 16 (59%) 
5 7 (28%) 11 (41%) 
Charlson comorbidity index 1 (1–3) 1 (1–2)
Current medication
Longacting bronchodilators 25 (100%) 27 (100%)
Shortacting bronchodilators 20 (80%) 25 (93%)
Inhaled corticosteroids 21 (84%) 22 (83%)
Oral steroids (maintenance) 7 (28%) 1 (4%)
Oxygen 8 (32%) 6 (22%)
Non-invasive ventilation 0 1 (4%)
Exacerbations previous year 4 (3–8) 3 (2–5)
Time since last exacerbation 
(weeks)
10 (4–21) 12 (10–32)
Total informal care (h per week) 17·4 (22·5) 13·8 (18·4)
Fat-free mass (kg) 49·5 (12·8) 46·9 (11·6)
Fat-free mass index (kg/m2) 17·1 (3·5) 16·7 (3·7)
6MWT
Distance (m) 209·2 (98·6) 221·5 (100·8)
Heart rate pre (beats per min) 86·3 (13·8) 85·36 (14·6)
Heart rate post (beats per min) 103·7 (17·7) 104·8 (16·7)
SpO2 pre 92·6 (2·7%) 93·0 (4·7%)
SpO2 post 88·0 (4·6%) 88·5 (6·7%)
End SOB Borg rating 4 (4–5) 5 (4–6)
End leg fatigue Borg rating 3 (1–4) 3 (2–5)
Primary limiting symptom
SOB 17 (68%) 15 (56%)
Leg fatigue 4 (16%) 2 (7%)
Both equally 4 (16%) 10 (37%)
Quadriceps MVC (kg) 24·5 (9·2) 23·1 (9·0)
Quadriceps MVC (% predicted) 58·9 (17·0) 57·3 (18·0)





(Continued from previous column)
Quadriceps twitch (kg) 6·68 (2·97) 7·07 (2·88)
RFcsa (mm2) 372·6 (147·2) 456·9 (172·5)
4 m gait speed (m/s) 0·79 (0·19) 0·83 (0·21)
Mean daily physical activity
Step count 2057 (1591) 1900 (1564)
Up-down transitions 40 (16) 33 (20)
Time spent upright (h) 3·31 (1·59) 3·09 (2·20)
CRQ*
Dyspnoea 2·29 (0·61) 2·58 (1·08)
Fatigue 3·23 (1·02) 3·12 (1·38)
Emotional 4·12 (1·28) 4·79 (1·14)
Mastery 4·84 (1·48) 4·78 (1·73)
SGRQ†
Symptoms 63·1 (22·0) 69·5 (17·1)
Activity 88·1 (9·8) 83·9 (20·4)
Eﬀ ect 53·2 (14·7) 49·9 (21·6)
EQ-5D index* 0·57 (0·20) 0·58 (0·28)
EQ-5D HRQL VAS* 58·1 (19·9) 55·0 (3·1)
Data are mean (SD), median (IQR), or n (%), unless otherwise stated. BMI=body-
mass index. FEV1=forced expiratory volume in 1 s. FVC=forced vital capacity. 
SpO2=ﬁ ngertip capillary oxygen saturation. MRC=Medical Reserch Council. 
SOB=shortness of breath. MVC=maximum voluntary contraction. RFcsa=rectus 
femoris cross-sectional area. CRQ=Chronic Respiratory Questionnaire. 
SGRQ=St George’s Respiratory Questionnaire. 6MWT=6-min walk test. 
EQ-5D=EuroQol 5-dimension. EQ-5D HRQL VAS=EuroQol 5-dimension health-
related quality of life visual analogue scale. *Scale interpretation: higher score 
better. †Scale interpretation: lower score better.
Table 1: Baseline characteristics of trial participants
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indicates better health status),25 and Chronic Respiratory 
Questionnaire (CRQ; total scale 0–28; higher score 
indicates better health status). Formal and informal care 
was assessed with the Client Service Receipt Inventory, in 
which participants reported health, voluntary, and social 
care services and carer support received over the 12-week 
trial period.26
Participants allocated to receive active NMES were, 
following the 6-week assessment, routinely invited to 
complete semistructured interviews to explore their 
experiences and views about the intervention, and any 
perceived eﬀ ect on their daily lives. Questions were 
open-ended and covered the areas of concern without 
being leading. Interviews were tape-recorded and 
transcribed verbatim.
Trial nurses and physiotherapists recorded adverse 
events during assessment visits and weekly telephone 
calls. These were classiﬁ ed without unmasking of group 
allocation by the trial lead (MM) as related, unrelated, or 
possibly related to treatment, using as much information 
as available to help to determine the potential attribution 
of the event.
Statistical analysis
Our sample size for the primary outcome, change in 
6MWT distance, was based on a COPD speciﬁ c clinically 
meaningful diﬀ erence of 54 m27 and an eﬀ ect estimate 
from a pilot trial of NMES in a comparable population.28 To 
detect this diﬀ erence between groups using a two sample 
t test with 90% power at the 0·05 signiﬁ cance level (two-
sided), assuming unequal variances, 25 participants per 
group were required. Allowing for a low (<5%) attrition 
rate based on pooled data from trials of similar duration,12 
we planned to recruit 52 participants overall.
The prespeciﬁ ed primary analysis was by intention to 
treat. Missing data were explored and reported according 
to cause.29 Missing data were handled by a multiple 
imputation approach (20 datasets), using a Monte Carlo 
Markov chain method and assuming a multivariate 
normal distribution.30 Missing outcome imputation was 
based on sex, baseline MRC dyspnoea scale, and baseline 
QMVC as moderators of 6MWT performance. The 
multiple imputation was implemented with SAS Proc 
MI and the results of mean change comparison were 
combined with SAS Proc MIanalyse.
Continuous data were expressed as mean (SD or 95% CI) 
and compared between groups with the Student’s t test. 
Non-normally distributed data were expressed as median 
(IQR). Categorical data were presented as percentages, and 
compared between groups with the Pearson χ² test. 
Outcomes were summarised as change from baseline. We 
used independent samples Student’s t test (two-sided) to 
compare change in 6MWT (primary outcome) and 
secondary outcomes at 6 weeks and 12 weeks, by trial 
group. Sensitivity analyses ﬁ rst used analysis of covariance 
to account for diﬀ erences in baseline values and then 
considered complete-cases only—ie, with paired 
observations—to account for possible eﬀ ect of data 
imputation. p<0·05 indicated statistical signiﬁ cance. 
Graphical presentations were produced with 
Prism 5 (GraphPad Software, San Diego, CA, USA).
Qualitative interview data were handled with NVivo 
version 7 (QSR International Pty Ltd, Melbourne, Austr) 
and content analysis was used to explore participants’ 
experience of the intervention and its eﬀ ect. We identiﬁ ed 
categories inductively from the interview data, with 
attention to terms and content, and used simple counting 
to discover consistency of views.
Neuromuscular electrical 
stimulation (n=25)
Placebo (n=27) Treatment diﬀ erence p value 
(two-sided t test)
Primary outcome: 6MWT distance (m) 29·9 (8·9 to 51·0) –5·7 (–19·9 to 8·4) 35·7 (10·5 to 60·9) 0·005
Secondary outcomes: quadriceps MVC (kg) 3·43 (1·3 to 5·6) 0·34 (–1·5 to 2·0) 3·09 (0·30 to 5·90) 0·028
Quadriceps twitch (kg) 0·99 (0·2 to 1·8) 0·30 (–0·4 to 1·0) 0·70 (–0·4 to 1·80) 0·17
RFCSA (mm2) 73·3 (42·6 to 104·1) 3·7 (–32·1 to 39·4) 70·0 (23·5 to 115·9) 0·003
Fat-free mass (kg) –1·49 (–4·3 to 1·3) –0·02 (–2·0 to 1·9) –1·46 (–4·8 to 1·9) 0·37
4MGS (m/s) 0·07 (0·0 to 0·1) 0·02 (0·0 to 0·1) 0·05 (0·0 to 0·1) 0·16
Daily step count –53 (–369 to 264) –89 (–485 to 307) 37 (–473 to 546) 0·65
Daily up-down transitions –1·5 (–7·8 to 4·7) 3·1 (–1·8 to 8·0) –4·6 (–12·5 to 3·2) 0·31
Daily time spent upright 0·08 (–0·5 to 0·7) –0·37 (–1·1 to 0·4) 0·45 (–0·5 to 1·4) 0·21
CRQ total score* 0·26 (–1·4 to 1·9) 0·43 (–0·5 to 1·4) –0·17 (–2·0 to 1·6) 0·77
SGRQ total score† 0·22 (–3·8 to 3·4) 0·07 (–3·1 to 3·2) –0·30 (–5·0 to 4·4) 0·78
EQ-5D index* –0·01 (–1·1 to 0·1) –0·01 (–0·1 to 0·1) –0·01 (–0·1 to 0·1) 0·78
EQ-5D HRQL VAS* 3·63 (–4·1 to 11·4) –2·39 (–8·6 to 3·8) 7·3 (–3·7 to 15·7) 0·20
Data are mean (95% CI). Missing data were imputed using a Monte Carlo Markov chain method with 20 datasets and assuming a multivariate normal distribution. 
6MWT=6-min walk test. MVC=maximum voluntary contraction. 4MGS=4 m gait speed. RFCSA=rectus femoris cross-sectional area. CRQ=Chronic Respiratory Questionnaire. 
SGRQ=St George’s Respiratory Questionnaire. EQ-5D=EuroQol 5-dimension. EQ-5D HRQL VAS=EuroQol 5-dimension health-related quality of life visual analogue scale. 
*Scale interpretation: higher score better. †Scale interpretation: lower score better.
Table 2: Estimates of eﬀ ect in primary and secondary outcome measures at 6 weeks
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Data were exported from the independent King’s 
Clinical Trials Unit system and analysis was completed 
by the trial statistician (WG) with SAS version 9.4 
(SAS Institute, Cary, NC, USA).
The trial was registered as ISRCTN15985261.
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had the ﬁ nal 
responsibility for the decision to submit the report for 
publication.
Results
Between June 29, 2012, and July 4, 2014, we screened 
73 patients; 62 met eligibility criteria, of whom 52 were 
randomly assigned; 25 were allocated to active NMES 
and 27 to placebo NMES (ﬁ gure 1). Most participants (56 
[81%]) were recruited from outpatient clinics or 
pulmonary rehabilitation services if a referred patient 
declined to take up a programme. Trial participants had a 
mean age of 70 years (SD 10) and severe disease by 
spirometry criteria (mean FEV1 31% predicted [SD 12]) 
with a median of four (IQR 2–5) exacerbations in the 
previous year (table 1). 22 participants (42%) had at least 
one comorbidity. Functional exercise capacity and 
physical activity were markedly low (mean 6MWT 
distance 216 m [SD 99] and daily step count 1980 
[SD 1563]; table 1). Participants required on average 
15·6 h (SD 20·3) of informal care each week 
(appendix p 1).
The prescribed programme consisted of 42 sessions 
lasting 1260 min in total. The mean number of recorded 
sessions was 34 (SD 14) in the active NMES group versus 
33 (18) in the placebo NMES group (p=0·84). The total 
duration of use was also similar (923 min [SD 546] vs 
938 min [588]; p=0·93). Initial to ﬁ nal NMES amplitudes 
were 49·3 mA (SD 9·8) to 72·6 mA (11·0) in the active 
group and 11·2 mA (SD 2·7) to 15·5 mA (2·8) in the 
placebo group. One participant from each group 
commenced pulmonary rehabilitation classes during the 
follow-up period, with three cumulative attendances 
between the 6-week and 12-week assessments in the 
active group and two in the placebo group.
Outcomes were obtained for 48 (92%) and 36 (69%) 
participants at 6 weeks and 12 weeks, respectively, with 
similar attrition rates across groups (ﬁ gure 1). Missing 
data and dropouts were not associated with baseline FEV1 
% predicted, exacerbation frequency, exercise capacity or 
health status, or trial group and were considered missing 
at random (data not shown). Consequently, analyses 
involved all randomly assigned participants.
We noted a signiﬁ cantly greater improvement in the 
primary endpoint, 6MWT distance, in the active NMES 
group compared with the placebo group (mean between-
group diﬀ erence 35·7 m (95% CI 10·5–60·9; eﬀ ect 
size 0·41; table 2; ﬁ gure 2). In the prespeciﬁ ed sensitivity 
analyses, adjustment for baseline 6MWT changed the 
p value from 0·005 to 0·004, and when complete-cases 
only were considered the between-group diﬀ erence for 
the primary outcome was increased by 1·0 m (appendix 
p 2).
This result was accompanied by positive changes in 
secondary outcomes related to muscle function: QMVC 
and RFcsa at 6 weeks (ﬁ gure 2). The change in TwQ 
favoured NMES though the eﬀ ect was only signiﬁ cant 
when adjusted for baseline (p=0·045). We observed no 
Figure 2: Functional exercise capacity (primary outcome), quadriceps muscle 
strength, and mass outcomes (secondary outcomes) by treatment group
Data are mean (95% CI) change. Shaded area represents treatment period. 
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signiﬁ cant between group diﬀ erences for gait speed, 
physical activity level, health status, or health-related 
quality of life outcomes at 6 weeks (table 2). Absolute 
changes for gait speed, step count, and time upright and 
EQ-5D visual analogue scale favoured active NMES. No 
consistent diﬀ erences in health status by SGRQ or CRQ 
were noted (table 2).
The treatment eﬀ ects waned after withdrawing NMES, 
such that at 12 weeks, no between-group diﬀ erences were 
noted (ﬁ gure 2; appendix p 3). The between group-
diﬀ erence in 6MWT distance was 7·3 m (95% CI –32·5 
to 47·0; p=0·50).
12 participants allocated to active NMES completed 
qualitative interviews. Perceived beneﬁ ts of NMES 
treatment were: greater ease in undertaking basic (eg, 
stair climbing) and extended (eg, shopping) activities of 
daily living, and an ability to complete physical activities 
for longer periods (panel). No participants reported 
negative experiences or views of the therapy.
The proportion of participants who had adverse events 
was similar between groups; 5 (20%) in the active NMES 
group and nine (33%) in the placebo group. 11 (21%) 
acute exacerbations requiring antibiotics were reported 
during the study period; four (16%) in the active NMES 
group and seven (26%) in the placebo NMES group 
(p=0·25). Nine (17%) of these exacerbations led to 
hospital admission, resulting in a short course of oral 
corticosteroids; three (12%) in the active NMES group 
and six (22%) in the placebo group (p=0·22). One 
participant (4%) received a diagnosis of laryngeal cancer. 
Two participants, one from each group, reported 
persistent erythema, which was considered to be possibly 
related to NMES and the use of adhesive electrodes.
Discussion
Our study shows that 6 weeks of NMES to the quadriceps 
improved functional exercise capacity in patients with 
severe COPD and incapacitating levels of breathlessness. 
The degree of change was lower than that reported in 
earlier unblinded studies and the level used to inform 
our sample size calculation, but exceeded the recent 
estimate for the minimally important diﬀ erence for 
6MWT distance which, based on all available evidence, 
lies between 25 m and 33 m.31 This eﬀ ect on functional 
exercise capacity was achieved by treating lower limb 
muscle dysfunction, with changes in quadriceps strength 
and mass evident in the active group, but not in the 
placebo group.
NMES programmes have previously been shown to be 
acceptable to people with severe COPD across 
community,32 inpatient rehabilitation,14 and intensive 
care settings.33 A strengthening eﬀ ect is expected with a 
pooled mean diﬀ erence in QMVC equivalent to about 
2·5 kg,12 consistent with the 3·1 kg diﬀ erence we noted. 
The risk proﬁ le for NMES is low and adverse events tend 
to reﬂ ect the populations being trialled, as was the case 
here. Localised muscle discomfort can be reported in the 
initial few days of use, but other side-eﬀ ects, including 
skin abrasion, bruising, or both are rare.12 NMES is a 
practical home-based therapy well suited to populations 
who have high levels of disability or symptom burden.12 
Although supervised pulmonary rehabilitation 
programmes oﬀ er much to address common symptoms 
of COPD, they are not suitable for the most severely 
aﬀ ected often house-bound patients, or at all times—eg, 
during an exacerbation of disease.10 These data support a 
role for NMES in the management of those unable or 
unwilling to engage with such programmes.
We purposefully selected patients with a high level of 
impairment as our systematic review suggested this 
group might respond favourably12 and this population 
can have diﬃ  culty accessing pulmonary rehabilitation. 
Many participants had declined or dropped out of a 
pulmonary rehabilitation programme suggesting that we 
reached the intended population. Sillen and colleagues14 
previously compared resistance training to high (75 Hz) 
and low (15 Hz) frequency NMES in patients with COPD 
and breathlessness and lower limb weakness, as part of 
an 8-week inpatient rehabilitation programme. 
Functional exercise performance, breathlessness, mood, 
and overall health status improved with both stimulation 
Panel: Illustrative quotes from qualitative interviews 
about perceived eﬀ ect of neuromuscular electrical 
stimulation on daily life
‘‘I think…I tend to walk better now…you see before me legs 
were a bit numbish, but once you had the machine…you tend 
to want to walk (yes) and then your legs feel a bit stronger…
My legs used to ache a lot you see but they haven’t ached 
since I’ve had that on…I used to ache I mean a lot, I was 
always worrying about my legs...I tend to walk a bit further 
now than what I did. I mean I’ve still got the breathing 
problem but my legs were still going. I could walk a lot 
further than what I did before...’’ (Man, 60 years)
‘‘…I was able to get around quicker um in a shorter time…I felt 
that it speeded up the process of strengthening my muscles 
so I can get up and walk as much as my body allows if you 
like…I found that I was able to, um, increase the length of time 
I was actually walking…I felt I could move around easier and 
wasn’t having to work so hard to do it’’ (Woman, 62 years)
‘‘…Well, I don’t think I can walk any faster…before I couldn’t 
go for a walk up the road. I couldn’t get no further than the 
corner, and I had to turn round and come back. But now I can 
get up as far as the paper shop, on a good day…I have my 
good days and my bad days, but I can get as far as the paper 
shop…go for a little walk round the shops...’’ (Man, 64 years)
‘‘…improvement in the muscles you’re looking at… enable me 
to get out of the chair easier, um, and with not too many 
details obviously get oﬀ  the toilet easier and so forth...I 
struggle with steps and it made it a little bit easier…’’ (Man, 
65 years 
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frequencies. They could not distinguish between the 
eﬀ ect of exercise and non-exercise programme 
components, although no signiﬁ cant diﬀ erences in 
muscle function outcomes were noted between 
high-frequency NMES and resistance training groups. 
When drawing any comparison between NMES and 
pulmonary rehabilitation, it is important to note the lack 
of observable eﬀ ect on physical activity level, health 
status, or quality of life following our programme. 
Although our trial was not powered to detect small 
changes in these secondary outcomes, pulmonary 
rehabilitation would typically lead to changes in these 
outcomes.8 The short NMES programme duration and 
absence of concurrent education and behavioural 
strategies might explain this limited response. Thus, 
based on current available data, NMES should not be 
regarded as a replacement for pulmonary rehabilitation. 
Instead, it might provide adjunct training,34 or be an 
alternative means to improve aspects of physical function 
in those unable to access pulmonary rehabilitation.
The link between peripheral muscle function and 
whole-body exercise performance is well described in 
COPD.35 The strength of association depends on the type 
of exercise test36 and the extent of ventilatory versus 
muscular impairment, which dictate the limiting factors 
to exercise performance.37 Vivodtzev and colleagues32 
highlighted this using NMES training. In their study, the 
level of improvement in exercise performance was 
related to stimulation intensity, and subsequent gains in 
quadriceps strength and reduced ventilatory demand 
during walking.32 In this trial, 6MWT distance improved 
in all but two participants at 6 weeks, although treatment 
response was heterogeneous. In a post-hoc analysis, we 
explored baseline FEV1, QMVC and NMES amplitude, 
and treatment compliance as possible mediators of 
treatment eﬀ ect, but none explained the variation in 
response. Vivodtzev and colleagues32 also showed gains 
in muscle mass following NMES, although we used 
ultrasonography and detected muscle hypertrophy 
without time-consuming or costly CT techniques. 
Because NMES was applied via skin electrodes, our 
imaging of rectus femoris as the most superﬁ cial of the 
quadriceps component muscles might have exaggerated 
the hypertrophic eﬀ ect of NMES. However, our ﬁ ndings 
are in keeping with changes noted after 8 weeks of lower 
limb resistance training.38 This measure of muscle mass 
has recently been shown as an independent risk factor of 
admission to hospital and survival39 and modiﬁ cation of 
risk via exercise intervention is an attractive prospect.
Participants perceived and reported speciﬁ c functional 
beneﬁ ts during daily life, which were not captured by 
standard questionnaires—eg, ﬁ nding toileting or stair 
climbing easier, or having improved outdoor mobility. 
The activities participants cited in the qualitative 
interviews generally depended on lower limb function, 
suggesting a link to the NMES therapy. The loss of ability 
to independently complete activities of daily living is 
pertinent to the trial population, who had substantial 
impairment at baseline and relied heavily on informal 
care. Indeed, 22 (42%) patients were enrolled with 
quadriceps strength below a functionally relevant cutoﬀ  
point that precludes the ability to sit-to-stand unaided.40 
The discrete changes in function following NMES might 
be early signs that the so-called deconditioning spiral is 
starting to be addressed, and with additional time and 
support, patients might translate gains in physical 
capacity into changes in their independence.
To our knowledge, our trial is the ﬁ rst to follow patients 
after NMES is withdrawn. Disappointingly, improve-
ments in exercise capacity and muscle function waned 
such that at 12 weeks between-group diﬀ erences were no 
longer signiﬁ cant. This ﬁ nding supports a causal eﬀ ect 
of NMES. The transient gain in muscle function points 
towards neural changes supplementing muscle 
anabolism, with increased sensitivity of neural synapses 
and better synchronisation of motor units during 
contractions.41 It also underscores the need to carefully 
time use within clinical practice as a standalone 
intervention. Potential roles might include preparing 
patients for supervised rehabilitation or enhancing 
functional recovery following acute illness. The latter 
indication has been questioned by the data of Greening 
and colleagues42 in which NMES was a key component of 
an early rehabilitation approach following admission to 
hospital for an acute exacerbation of chronic respiratory 
disease. However, in that trial, only modest doses of 
exercise training could be oﬀ ered during the short 
hospital stays, and compliance to the home-based 
intervention was poor. Importantly, uptake of formal 
outpatient pulmonary rehabilitation, oﬀ ered to both 
groups after 3 months, was lower in the intervention 
group than in the usual care control group. This health 
behaviour suggests that patients receiving the early 
intervention might have considered their rehabilitation 
needs to have already been met.43 Therefore, when 
treatments like NMES are introduced into clinical 
practice, clear communication about their role and what 
they cannot replace is paramount.
Strengths of this trial include the successful masking of 
participants and outcome assessors, a feature not identiﬁ ed 
in other NMES trials.12 Participant masking is diﬃ  cult for 
any physical intervention, but the use of an outwardly 
identical placebo device with a limited output and with 
careful randomisation conduct and communication 
ensured this was possible. A breadth of validated outcome 
measures, oﬀ ering volitional and non-volitional 
assessments of muscle mass and function, provided 
strong mechanistic data to understand the mechanisms 
behind our primary ﬁ nding. Our follow-up and qualitative 
data proved to better understand the clinical role of NMES 
compared with existing treatments. Finally, the high 
uptake of participants across multiple sites, low attrition 
rate, along with the pragmatic delivery of treatment that 
involved diﬀ erent staﬀ  and light supervision, enhances the 
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external validity of our ﬁ ndings. We perceive the delivery of 
NMES in this trial is closer to how it would be oﬀ ered in 
clinical practice than in previous reports.
There are limitations to consider. We were not able to 
mask the nurses and physiotherapists who were 
involved in recording of adverse event data, although 
events were classiﬁ ed without unmasking of group 
allocation. We perceive our placebo model to have been 
successful, but we cannot entirely rule out an anabolic 
eﬀ ect, and incidental features of NMES such as 
dedicated time for self-management might have 
aﬀ ected participant behaviour. Our sample size was 
informed by eﬀ ect estimate data from a pilot study and 
an established minimally important diﬀ erence for 
COPD, and the expected diﬀ erence of 54 m was not 
reached. Nonetheless, our homogeneous sample and 
well standardised assessments contributed to between-
group diﬀ erences that were signiﬁ cant and exceeded 
updated minimally important diﬀ erences for our 
primary endpoint.31 We were not powered to detect 
small changes in health status that might be expected 
following this modest intensity training. We noted a 
small number of hospital admissions during the short 
trial period. Although the number of exacerbations, 
hospital admissions, and courses of oral corticosteroids 
was higher in the placebo group than in the active 
group, this was unlikely to account for the diﬀ erences 
in functional exercise capacity, which remained stable, 
and was enhanced following active NMES. Based on 
this research, future work should consider trialling 
longer programmes of NMES, potentially those that 
use improvements in function to dovetail into 
pulmonary rehabilitation, or add behaviour change and 
education components to NMES to enhance health 
status and quality of life. Once optimised, the eﬀ ect of 
an NMES-based approach on outcomes pertaining to 
patient independence and health service use could be 
evaluated.
In conclusion, a 6-week programme of NMES 
improved functional exercise capacity in patients with 
severe COPD by enhancing quadriceps muscle mass and 
function. These data support a role for NMES in the 
management of those unable or unwilling to engage with 
current pulmonary rehabilitation programmes. The 
short duration of eﬀ ect and little eﬀ ect on health status 
suggest a need to explore longer programmes, or adding 
education and behaviour change interventions as part of 
a broader rehabilitation package.
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